Diffuse large B-cell lymphoma(DLBCL)is the most common type of non Hodgkin's lymphoma.The current treatment plan can significantly improve the prognosis of patients,but about 30%-40%of DLBCL patients still experience drug resistance and relapse after treatment.For patients with refractory/relapse DLBCL,clinical treatment remains difficult and their prognosis is poor.Allogeneic hematopoietic stem cell transplantation(allo-HSCT)remains one of the most important curative methods for refractory/relapse DLBCL patients.This article will review the role and progress of allo-HSCT in the treatment of refractory/relapse DLBCL.